DP
ABBV icon

DDD Partners’s AbbVie ABBV Stock Holding History

DDD Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
4,388
-87,009
-95% -$18.7M 0.07% 78
2026
Q1 		$19.9M Buy
91,397
+2,757
+3% +$612K 1.37% 20
2025
Q4 		$20.3M Buy
88,640
+234
+0.3% +$53.3K 1.29% 21
2025
Q3 		$20.5M Sell
88,406
-18,274
-17% -$3.72M 1.3% 16
2025
Q2 		$19.8M Sell
106,680
-5,843
-5% -$1.09M 2.12% 20
2025
Q1 		$23.6M Sell
112,523
-12,822
-10% -$2.49M 2.86% 10
2024
Q4 		$22.3M Buy
125,345
+11,168
+10% +$2.05M 2.74% 12
2024
Q3 		$22.5M Buy
114,177
+507
+0.4% +$94.6K 2.45% 16
2024
Q2 		$19.5M Buy
113,670
+365
+0.3% +$60.5K 2.26% 17
2024
Q1 		$20.6M Sell
113,305
-19,002
-14% -$3.27M 2.52% 13
2023
Q4 		$20.5M Sell
132,307
-822
-0.6% -$120K 2.76% 12
2023
Q3 		$19.7M Sell
133,129
-2,544
-2% -$373K 2.85% 8
2023
Q2 		$18.3M Buy
135,673
+134,327
+9,980% +$19.7M 2.53% 16
2023
Q1 		$215K Buy
1,346
+5
+0.4% +$764 0.03% 75
2022
Q4 		$217K Buy
+1,341
New +$206K 0.03% 73

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DDD Partners's ABBV Position: Q2 2026 in Review

DDD Partners reduced its AbbVie (ABBV) stake by 95% in Q2 2026, selling an estimated $18.7M and leaving 4,388 shares worth $1.1M. The position accounts for 0.07% of the portfolio, ranked #78.

DDD Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $23.6M in Q1 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • DDD Partners held 4,388 shares of AbbVie worth $1.1M as of Q2 2026.
  • DDD Partners sold 87,009 AbbVie shares in Q2 2026, an estimated $18.7M.
  • AbbVie made up 0.07% of DDD Partners's portfolio in Q2 2026, its #78 holding.
  • DDD Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • DDD Partners's AbbVie position peaked at $23.6M in Q1 2025.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DDD Partners's 13F filing for Q2 2026, filed 5 Aug 2026.